arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Candel Therapeutics, Inc.

CADL

$10.58 0.00 (0.00%) at close

7 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Candel Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $560.3M

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -93.0% ↘

FCF / Share $-0.73 ↗

Trailing P/E —

Price / Book 11.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$125.00K

— 0.0% —

Net Income Profit after all expenses

$-38.18M

↑ +30.8% —

FCF / Share Free cash flow per share

$-0.73

↑ +14.0% —

Long-Term Debt Long-term obligations

$11.63M

↑ +2308.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	—	—	—	0.0% Caution Caution Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-100%)	0.0% Caution Caution Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-100%)	—	—
EPS Growth YoY (%)	58.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-32.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-101.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	66.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	30.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-45.4% Weak ↑ Weak Improving Year-over-year change in net income	-101.9% Weak ↓ Weak Declining Year-over-year change in net income	48.0% Excellent Excellent Year-over-year change in net income	-104.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	14.0% Fair ↑ Fair Improving Year-over-year change in free cash flow	28.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-5.7% Weak Weak Year-over-year change in free cash flow	10.9% Fair Fair Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
FCF / Net Income (x)	1.02x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	0.49x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.74x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-93.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-50.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-124.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-57.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	47.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-38.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-31.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-93.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-28.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-36.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-73.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-590%)	-83.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-655%)	-297.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-2085%)	-39.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-363%)	-56.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-475%)	75.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+400%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	—	—	0.91x Fair Fair Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+52%)	—	—	-0.02x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-103%)	—
Interest Coverage (x)	-22.78x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-15.97x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-14.79x Weak Weak Operating income divided by interest expense Optimal: > 5x	-20.33x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-119.73M	$-102.65M	$-23.78M	$-70.06M	$-82.64M	$-34.57M	—
Debt / EBITDA (x)	—	—	-0.31x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	-0.04x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	—	—	—	$0.00	$0.01	—	—
Basic EPS, GAAP (USD)	$-0.72	$-1.74	$-1.31	$-0.65	$-1.91	—	—
Free Cash Flow per Share (USD)	$-0.73	$-0.85	$-1.20	$-1.14	$-1.27	—	—
Book Value per Share (USD)	$0.95	$1.42	$0.44	$1.65	$2.24	$-2.03	—
Tangible Book Value per Share (USD)	$0.95	$1.42	$0.44	$1.65	$2.24	$-2.03	—
Basic Weighted Avg Shares (shares)	52.96M	31.68M	28.94M	28.82M	18.87M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$112.39M	$66.28M	$22.61M	$66.33M	$79.58M	$30.43M	—
LT Debt (USD)	—	—	$11.63M	—	—	$483.00K	—
Total Equity (USD)	$51.92M	$66.33M	$12.74M	$47.71M	$64.14M	$-23.56M	$-8.04M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	$125.00K	$125.00K	$125.00K	—
Depreciation Expense (USD)	$845.00K	$990.00K	$960.00K	$778.00K	$232.00K	$91.00K	—
Net Income, GAAP (USD)	$-38.18M	$-55.18M	$-37.94M	$-18.79M	$-36.12M	$-17.68M	—
Operating Cash Flow (USD)	$-38.31M	$-27.02M	$-34.24M	$-31.42M	$-22.22M	$-9.07M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Candel Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CADL with peers